4C Labs, the Guernsey based phyto pharma company focused on the medical cannabis space, has been granted Importation and Distribution licences by the UK Medicines and HealthCare Products Regulatory Authority (MHRA).
The recently obtained **MS and WDA licences allow 4C Labs to import low cost, high quality, cannabis based medicines into the UK from a global network of EU GMP suppliers as well as from the 4C Labs production facility in Guernsey. The licences also enable 4C labs UK to distribute cannabis based medicines to registered UK and Channel Island Pharmacies.
The UK requires companies to reliably provide low cost, high quality medical cannabis medicines to patients. Supply chain reliability, product quality and pricing all remain issues that require solutions for many patients suffering from chronic pain, cancer, sleep and anxiety issues.
4C Labs sees the UK Medical Cannabis market expanding significantly over the next 5 years with growth rates that mirror previously legalized medical markets. The new licencing will enable 4C Labs to establish a dominant position in a rapidly growing UK Medical Cannabis market.
4C Labs has now completed the external works on the its Guernsey cultivation facility. Once the Series A fundraising round is complete 4C Labs will commence work on the interior fit out of the facility.
The 4C Health Specialist Clinic and 4C Labs distribution will be launched in Q1 of 2023, with the aim of providing better quality products at a discount to current market pricing to Guernsey and UK patients.
Series A funding raise
The new MS/WDA Licences were the final component required by 4C Labs to begin executing a strategy that has taken 3 years to develop. On the back of this recent success, 4C Labs will commence a Series A funding raise in September. Until the funding raise is complete, 4C Labs is looking to speak to sophisticated investors to raise interim capital up to £1 million. Interim capital will cover overhead costs and move 4C Labs to generating revenue.
Greg Dobbin (shown in the main picture), CEO of 4C Labs, commented: “We are extremely excited to have received approval for a MS Licence and a WDA licence. This is a major step forward for Guernsey and UK patients who are eligible for medical cannabis and are looking for a cost effective curated product line that meets their budgets and their medical needs.
“This licencing approval moves 4C Labs into the position as the only Medical Cannabis company in the Channel Islands and the UK to hold a CQC Clinic registration, Production Licence in Guernsey and WDA/MS Licences. The road to achieving this milestone was complex but the pace of development matches our philosophy.
“4C Labs has a very long term view of the Phyto Pharma landscape in the Guernsey and the UK and a keen understanding that licencing and regulation drive the new market forward. Our pace of development and low cost approach matches our philosophy of carefully building 4C Labs’ business brick by brick.”
What is a MS Licence and WDA licence?
- Manufacturer’s ‘Specials’ Licence (MS): A licence and Good Manufacturing Distribution Practice (GMDP) certification issued by the MHRA to import and release finished product from any EU GMP-certified facility qualified by 4C Labs (EU and ex EU), and distribute (supply and sell) CBPMs to registered pharmacies in the UK.
- Wholesale Distribution Authorisation (WDA(H)): A licence and Good Distribution Practice (GDP) certification issued by the MHRA to import finished product from EU GMP-certified facilities qualified by 4C Labs within the EU, and distribute (supply and sell) CBPMS to registered pharmacies in the UK.